【レポートの概要（一部）】
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chemotherapy Induced Neutropenia Overview 10
Therapeutics Development 11
Pipeline Products for Chemotherapy Induced Neutropenia – Overview 11
Pipeline Products for Chemotherapy Induced Neutropenia – Comparative Analysis 12
Chemotherapy Induced Neutropenia – Therapeutics under Development by Companies 13
Chemotherapy Induced Neutropenia – Therapeutics under Investigation by Universities/Institutes 16
Chemotherapy Induced Neutropenia – Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Chemotherapy Induced Neutropenia – Products under Development by Companies 21
Chemotherapy Induced Neutropenia – Products under Investigation by Universities/Institutes 24
Chemotherapy Induced Neutropenia – Companies Involved in Therapeutics Development 25
Bio-Ker s.r.l 25
Biogenomics Limited 26
Bolder Biotechnology, Inc. 27
Cellerant Therapeutics, Inc. 28
Coherus BioSciences, Inc. 29
Dong-A Socio Group 30
Generon (Shanghai) Corporation Ltd. 31
Hanmi Pharmaceuticals, Co. Ltd. 32
Io Therapeutics, Inc. 33
Mycenax Biotech Inc. 34
Myelo Therapeutics GmbH 35
Octapharma AG 36
PharmaEssentia Corporation 37
Reliance Life Sciences Pvt. Ltd. 38
Richter Gedeon Nyrt. 39
Sandoz Inc. 40
Sandoz International GmbH 41
Teva Pharmaceutical Industries Limited 42
UAB Profarma 43
USV Limited 44
Welichem Biotech Inc. 45
XBiotech USA, Inc. 46
Chemotherapy Induced Neutropenia – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 50
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
balugrastim – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BBT-007 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
BBT-015 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
BBT-018 – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BK-0026 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cell Therapy for Chemotherapy Induced Neutropenia – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
F-627 – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
filgrastim – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
filgrastim – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
filgrastim – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
filgrastim – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim (recombinant) – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GW-003 – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
HM-10460A – Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
IRX-4310 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
lipegfilgrastim – Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Myelo-001 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
pegfilgrastim – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pegfilgrastim – Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
pegfilgrastim – Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
pegfilgrastim – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
pegfilgrastim – Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
pegfilgrastim – Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
pegfilgrastim – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
pegfilgrastim – Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Recombinant Protein for Chemotherapy Induced Neutropenia – Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
romyelocel-L – Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TXA-302 – Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
WBI-2100 – Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Chemotherapy Induced Neutropenia – Recent Pipeline Updates 92
Chemotherapy Induced Neutropenia – Dormant Projects 98
Chemotherapy Induced Neutropenia – Discontinued Products 100
Chemotherapy Induced Neutropenia – Product Development Milestones 101
Featured News & Press Releases 101
Dec 08, 2014: Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at the American Society of Hematology 56th Annual Meeting at San Francisco 101
Sep 09, 2014: Spectrum Pharmaceuticals Makes Decision to Advance SPI-2012, a Novel Long-Acting GCSF, to Phase 3 Due to Positive Phase 2 Results in its Collaboration Program with Hanmi Pharm 102
May 28, 2014: Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 – A Novel Long-Acting Granulocyte Colony Stimulating Factor to Treat Chemotherapy-induced Neutropenia 103
Mar 25, 2014: Sandoz receives approval for biosimilar filgrastim in Japan 103
Nov 18, 2013: Teva announces Launch of LONQUEX Injection 104
Jul 22, 2013: Zarzio overtakes Neupogen and Granocyte to become most prescribed daily G-CSF in Europe 105
Jun 03, 2013: Teva’s Lonquex Receives Positive Opinion From CHMP For Reduction Of Chemotherapy-induced Neutropenia 105
Apr 25, 2013: Sandoz Files For Marketing Authorization Of Biosimilar Filgrastim In Japan 106
Apr 08, 2013: Spectrum Pharma Initiates Phase II Study Of Long-acting GCSF Drug Candidate SPI-2012 For Treatment Of Chemotherapy-induced Neutropenia 106
Jan 07, 2013: Generon Initiates Phase I/II Clinical Trial Of F-627 For Treatment Of Breast Cancer In China 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109
【レポート販売概要】
■ タイトル：化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の治療薬パイプライン動向（2015年上半期版）■ 英文：Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015
■ 発行日：2015年1月22日
■ 調査会社：Global Markets Direct
■ 商品コード：GMDHC6036IDB
■ 調査対象地域：グローバル
- Koninklijke Vopak N.V.：石油・ガスバリューチェーン分析レポート2013Koninklijke Vopak N.V. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Koninklijke Vopak N.V." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Koninklijke Vopak N.V.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The repor …
- 世界のネットワーク・アプリケーション及びソフトウェア市場動向（2012-2016）TechNavio's analysts forecast the Global Network Applications and Software market to grow at a CAGR of 7.41 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapidly growing network traffic. The Global Network Applications and Software market has also been witnessing an increasing number of mergers and acquisitions. However, the security issues in …
- フッ素樹脂の世界市場：PTFE、PVDF、FE、フルオロエラストマ、PCTFE、ETFE、ECTFE、PFAThis report on fluoropolymers market covers latest market trends and forecasting reports for the global fluoropolymers industry. Fluoropolymers are polymeric resins in which some or all of the hydrogen atoms in the polymer chain have been replaced by fluorine. They offer a combination of good chemical resistance, excellent electrical insulation properties, and favorable mechanical properties. Thes …
- バイオチップの世界市場：DNAチップ、ラボオンチップ、タンパク質チップThe biochips market is expected to reach USD 17.75 Billion by 2020 from USD 7.63 Billion in 2015, growing at a CAGR of 18.4% during the forecast period (2015–2020). Increasing adoption of personalized medicine, growing applications of biochips, and technological advancements are the major drivers for the biochips market. However, unclear regulatory guidelines, high instrumentation costs, and absol …
- 車両用知能型システムの世界市場：道路状況認識、先進運転者支援・監視、構成品、車両種類、地域別分析The global vehicle intelligence systems market is projected to grow from USD 11.29 Billion in 2016 to USD 20.11 Billion by 2021, registering a CAGR of 12.24% during the forecast period. The report covers two major vehicle categories for vehicle intelligence systems that is, passenger cars and commercial vehicles. Changing consumer preferences and growing safety and environmental concerns have play …
- 自動車用ブッシュの世界市場予測（～2025年）“The significant increase in production in the global automotive industry is expected to drive the automotive bushing market.” The global automotive bushing market is projected to grow from an estimated USD 132.20 billion in 2018 to USD 175.31 billion by 2025, at a CAGR of 4.11% from 2018 to 2025. The market is anticipated to grow due to the growing vehicle production, shifting focus toward lightw …
- 施設園芸の世界市場2016-2020：プラスチック、ガラスAbout Greenhouse Horticulture Greenhouse horticulture is the production of crops within a structured shelter, which ensures customized growing conditions. A majority of greenhouse structures are made of plastic, followed by glass, and other materials. Greenhouses protect crops from diseases, pests, and various unfavorable weather conditions. The benefits of greenhouse horticulture over conventiona …
- ポリアルキレングリコールの世界市場：ポリエチレングリコール(PEG) 、ポリプロピレングリコール(PPG)The global PAGs market was estimated to be worth USD 1.33 Billion in 2014 and is projected to reach USD 2.62 Billion by 2020, at a CAGR of 11.7% between 2015 and 2020. This high growth of the market is owed to the increasing demand from end-use industries in the U.S., Germany, France, China, India, and Japan. The increased usage of PAGs in a variety of applications is also one of the key factor dr …
- 世界のモバイル通信への企業支出動向（2012-2016）TechNavio's analysts forecast the Global Enterprise Spending on Mobile Communication to grow at a CAGR of 4.72 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing need for enterprise mobility. The Global Enterprise Spending on Mobile Communication space has also been witnessing the growing availability of corporate communication packages. …
- モバイルコンピューティング端末の世界市場：スマートフォン、タブレットPC、ポータブルPC、Eリーダー、ゲーム機About Mobile Computing Devices Mobile computing devices are devices that have an operating system along with connectivity and are able to perform basic functions as those of a standard personal computer. In this respect, the devices that fall under this category are listed below: • Smartphones • Tablet • Portable PCs • E-readers • Gaming Consoles Each of the above-listed devices is utilized either …
- エンターテインメント用ロボットの世界市場：教育ロボット、ロボットペットAbout the Entertainment Robots Market Entertainment robots are developed for utilitarian purpose in domestic settings to entertain humans, especially children, elderly, guests, or clients. These robots are equipped with microphones, and can recognize voices and cameras to avoid obstacles and identify faces. They can converse, move, sing, dance, and interact with people. Manufacturers are developin …
- 店舗内販売及びショッパーエンゲイジメント改善、ショールーミング対応のモバイルソリューション（Wireless Solutions to Improve In-store Sales, Optimize Shopper Engagement, and Combat "Showrooming"）The retail industry is speedily evolving with spectacular changes in consumer buying behavior. Retailers need to have new strategies to satisfy their customers and enrich their buying experience. Online shopping is getting popular day by day and it is more popular than ever, but brick-and-mortar stores still dominate and have a larger share of the pie. Retailers are now thinking that they need to …
- B細胞非ホジキンリンパ腫：世界の臨床試験レビュー（2014年上半期）B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of t …
- 動力式芝刈り機の世界市場2016-2020About Power Lawn Mowers Power lawn mowers have evolved from the traditional hand-guided mowers to automatic electric mowers. Advancements in technology have led to the development of lightweight power lawn mowers and battery-powered lawn mowers. The robotic lawn mower is one such innovative product available in the market. Increasing availability of such products with improved features has contrib …
- Polyoxin Bの世界市場POLYOXIN B (CAS 19396-06-6) Market Research Report 2012 presents comprehensive data on polyoxin b markets globally and regionally (Europe, Asia, North America etc.) The report includes polyoxin b description, covers its application areas and related patterns. It overviews polyoxin b market, names polyoxin b producers and indicates its suppliers. Besides, the report provides polyoxin b prices in re …
